Therapeutic Trajectories in Human Prion Diseases.

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Prion diseases are fatal neurodegenerative disorders caused by misfolded prion proteins (PrPSc) originating from cellular prion protein (PrPC).
• Current treatments for prion diseases are lacking due to challenges in early diagnosis and understanding prion neurotoxicity.
• Despite extensive research, effective therapies remain elusive, necessitating novel therapeutic strategies.

Purpose of the Study:

• To explore current and emerging therapeutic strategies for treating prion diseases.
• To discuss the challenges and potential of various treatment modalities, including small molecules, immunotherapies, and genetic approaches.
• To highlight the importance of early detection and collaborative research in advancing prion disease treatment.

Main Methods:

• Review of small molecule inhibitors targeting PrPSc destabilization or PrPC homeostasis.
• Analysis of immunotherapeutic approaches, including passive and active immunization strategies.
• Exploration of genetic tools like RNA interference (RNAi) and CRISPR-based technologies for PrPC reduction.

Main Results:

• Small molecules show promise in inhibiting prion replication and may overcome strain-dependent resistance.
• Immunotherapies offer potential but face hurdles in brain penetration and neurotoxicity.
• Genetic tools provide targeted approaches to reduce PrPC expression, preventing PrPSc formation.

Conclusions:

• A multifaceted therapeutic approach is essential for treating prion diseases.
• Advancements in early detection, drug delivery, and interdisciplinary research are crucial for clinical breakthroughs.
• Ongoing clinical trials, such as the PrProfile trial for ION717, represent significant progress in developing novel prion disease treatments.